Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NovoCure Limited - Ordinary Shares
(NQ:
NVCR
)
13.78
-0.25 (-1.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,014,374
Open
13.77
Bid (Size)
13.69 (1)
Ask (Size)
13.99 (1)
Prev. Close
14.03
Today's Range
13.55 - 14.13
52wk Range
10.87 - 34.13
Shares Outstanding
103,647,871
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
October 15, 2025
From
Novocure
Via
Business Wire
Novocure to Report Third Quarter 2025 Financial Results
October 01, 2025
From
Novocure
Via
Business Wire
Performance
YTD
-54.1%
-54.1%
1 Month
+8.7%
+8.7%
3 Month
-15.0%
-15.0%
6 Month
-11.6%
-11.6%
1 Year
-22.9%
-22.9%
More News
Read More
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
September 29, 2025
From
Novocure
Via
Business Wire
Earnings Scheduled For July 24, 2025
July 24, 2025
Via
Benzinga
NovoCure Earnings Preview
July 23, 2025
Via
Benzinga
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
September 15, 2025
From
Novocure
Via
Business Wire
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts
August 29, 2025
Via
The Motley Fool
Novocure Announces Upcoming Investor Events
August 28, 2025
From
Novocure
Via
Business Wire
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
August 25, 2025
From
Novocure
Via
Business Wire
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
August 20, 2025
From
Novocure
Via
Business Wire
Top 3 Health Care Stocks That May Explode In July
July 28, 2025
Via
Benzinga
NovoCure Q2 Revenue Jumps 6 Percent
July 24, 2025
Via
The Motley Fool
Topics
World Trade
12 Health Care Stocks Moving In Thursday's Intraday Session
July 24, 2025
Via
Benzinga
Novocure: Steady Ahead of Key Milestones
July 24, 2025
Via
The Motley Fool
Novocure Reports Second Quarter 2025 Financial Results
July 24, 2025
From
Novocure
Via
Business Wire
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday
July 08, 2025
Via
Benzinga
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
July 01, 2025
From
Novocure
Via
Business Wire
Novocure to Report Second Quarter 2025 Financial Results
June 30, 2025
From
Novocure
Via
Business Wire
Demystifying NovoCure: Insights From 4 Analyst Reviews
June 27, 2025
Via
Benzinga
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
June 08, 2025
Via
Benzinga
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
June 02, 2025
Via
Benzinga
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
May 31, 2025
From
Novocure
Via
Business Wire
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street
May 28, 2025
Via
The Motley Fool
Novocure Announces Upcoming Investor Events
May 27, 2025
From
Novocure
Via
Business Wire
Why NovoCure Stock Skyrocketed This Week
April 25, 2025
Via
The Motley Fool
Topics
Earnings
Stocks
Frequently Asked Questions
Is NovoCure Limited - Ordinary Shares publicly traded?
Yes, NovoCure Limited - Ordinary Shares is publicly traded.
What exchange does NovoCure Limited - Ordinary Shares trade on?
NovoCure Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for NovoCure Limited - Ordinary Shares?
The ticker symbol for NovoCure Limited - Ordinary Shares is NVCR on the Nasdaq Stock Market
What is the current price of NovoCure Limited - Ordinary Shares?
The current price of NovoCure Limited - Ordinary Shares is 13.78
When was NovoCure Limited - Ordinary Shares last traded?
The last trade of NovoCure Limited - Ordinary Shares was at 10/17/25 04:00 PM ET
What is the market capitalization of NovoCure Limited - Ordinary Shares?
The market capitalization of NovoCure Limited - Ordinary Shares is 1.43B
How many shares of NovoCure Limited - Ordinary Shares are outstanding?
NovoCure Limited - Ordinary Shares has 1B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.